Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJLK | ISIN: US42328V8019 | Ticker-Symbol: 26H
NASDAQ
23.04.25
21:39 Uhr
0,295 US-Dollar
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
HELIUS MEDICAL TECHNOLOGIES INC Chart 1 Jahr
5-Tage-Chart
HELIUS MEDICAL TECHNOLOGIES INC 5-Tage-Chart

Aktuelle News zur HELIUS MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiHELIUS MEDICAL TECHNOLOGIES, INC. - 8-K, Current Report2
04.04.HELIUS MEDICAL TECHNOLOGIES, INC. - 8-K, Current Report1
HELIUS MEDICAL Aktie jetzt für 0€ handeln
25.03.HELIUS MEDICAL TECHNOLOGIES, INC. - S-8, Securities to be offered to employees in employee benefit plans1
25.03.HELIUS MEDICAL TECHNOLOGIES, INC. - 10-K, Annual Report2
13.03.Helius Medical launches AI-driven BCI subsidiary1
13.03.Helius Medical gründet KI-gestützte BCI-Tochtergesellschaft2
13.03.Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface ("BCI") Technology Private Subsidiary1
07.02.HELIUS MEDICAL TECHNOLOGIES, INC. - 8-K, Current Report-
31.01.Helius Medical Technologies files to sell 6.21M shares of class A common stock1
24.01.HELIUS MEDICAL TECHNOLOGIES, INC. - 8-K, Current Report-
22.01.Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy on Gait Deficit Improvement in Multiple Sclerosis from the PoNS Therapeutic Experience Program ...168--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically...
► Artikel lesen
22.01.Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market3
21.01.Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target152--128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by end of January-- --The stroke registrational program...
► Artikel lesen
15.01.HELIUS MEDICAL TECHNOLOGIES, INC. - 8-K, Current Report2
23.12.24HELIUS MEDICAL TECHNOLOGIES, INC. - 8-K, Current Report1
23.12.24Helius Medical Technologies, Inc.: Helius Announces First Portable Neuromodulation Stimulator (PoNS) System Sale to the Veterans Affairs (VA) Healthcare System4
18.11.24Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS) Device4
18.11.24Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives195NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation...
► Artikel lesen
18.11.24HELIUS MEDICAL TECHNOLOGIES, INC. - 8-K, Current Report2
12.11.24HELIUS MEDICAL TECHNOLOGIES, INC. - 10-Q, Quarterly Report-
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1